Cantor Fitzgerald L. P. Makes New Investment in Entrada Therapeutics, Inc. $TRDA

Cantor Fitzgerald L. P. purchased a new stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 67,334 shares of the company’s stock, valued at approximately $391,000. Cantor Fitzgerald L. P. owned about 0.18% of Entrada Therapeutics at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Algert Global LLC bought a new position in Entrada Therapeutics during the third quarter valued at about $753,000. Alliancebernstein L.P. increased its stake in shares of Entrada Therapeutics by 7.1% during the 3rd quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock worth $141,000 after purchasing an additional 1,620 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Entrada Therapeutics by 55.6% in the 3rd quarter. Ameriprise Financial Inc. now owns 69,926 shares of the company’s stock worth $406,000 after purchasing an additional 24,980 shares during the period. Occudo Quantitative Strategies LP lifted its stake in Entrada Therapeutics by 190.6% in the third quarter. Occudo Quantitative Strategies LP now owns 29,486 shares of the company’s stock valued at $171,000 after purchasing an additional 19,338 shares during the last quarter. Finally, Two Sigma Investments LP purchased a new stake in Entrada Therapeutics in the third quarter worth $541,000. Institutional investors own 86.39% of the company’s stock.

Insider Buying and Selling at Entrada Therapeutics

In other news, CFO Kory James Wentworth sold 11,388 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $13.02, for a total value of $148,271.76. Following the completion of the sale, the chief financial officer directly owned 121,510 shares of the company’s stock, valued at approximately $1,582,060.20. This trade represents a 8.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Nathan J. Dowden sold 11,894 shares of the stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $13.05, for a total transaction of $155,216.70. Following the completion of the transaction, the chief operating officer directly owned 198,588 shares of the company’s stock, valued at approximately $2,591,573.40. The trade was a 5.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 39,475 shares of company stock valued at $508,069 over the last 90 days. Company insiders own 7.59% of the company’s stock.

Entrada Therapeutics Stock Performance

Shares of NASDAQ:TRDA opened at $12.69 on Monday. The firm has a market capitalization of $485.77 million, a PE ratio of -3.67 and a beta of -0.12. Entrada Therapeutics, Inc. has a 52-week low of $4.93 and a 52-week high of $13.65. The firm has a fifty day moving average of $11.34 and a 200 day moving average of $8.99.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.38. The firm had revenue of $1.30 million during the quarter, compared to analyst estimates of $7.41 million. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. On average, sell-side analysts forecast that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TRDA has been the subject of several research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Monday, December 29th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Entrada Therapeutics in a research report on Wednesday, February 18th. Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Guggenheim upgraded Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Finally, Oppenheimer initiated coverage on Entrada Therapeutics in a research report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.50.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.